Does local vancomycin powder impregnated with autogenous bone graft and bone substitute decrease the risk of deep surgical site infection in degenerative lumbar spine fusion surgery?—An ambispective study

Po-Hsin Chou1,2, Hsi-Hsien Lin1,2, Yu-Cheng Yao1,2, Ming-Chau Chang1,2, Chien-Lin Liu1,2 and Shih-Tien Wang1,2*

Abstract

Background  Deep surgical site infection (DSSI) is one of the most challenging complications in lumbar fusion surgery. Few investigations examined the effect of vancomycin powder mixed with autogenic bone graft (ABG) and bone substitutes on preventing DSSI in degenerative lumbar fusion surgeries as well as any interference with bony fusion. The aim of the study was to investigate the effects of ABG along with bone substitutes as a local vancomycin delivery system on preventing DSSI in lumbar instrumented fusion and compared with those who did not use vancomycin powder.

Methods  From January, 2015 through December, 2015, a one-year prospective study using vancomycin powder mixed with ABG and bone substitute for degenerative lumbar fusion surgeries as vancomycin (V) group, 1 gm vancomycin for 2 and 3-level, and 2 gm for more than 3-level instrumentation. From December, 2013 through December 2014, patients received degenerative lumbar fusion surgeries without using vancomycin before the vancomycin protocol were retrospectively enrolled as non-vancomycin (NV) group. Vancomycin concentration was checked at post-operative days 1 and 3 for both the serum and drainage. Patients’ demographic data, microbiology reports, fusion status and functional outcomes were evaluated.

Results  One hundred and ten patients were enrolled prospectively in the V group, and 86 for the NV group. After an average 41 months follow-up (range, 36–54), 3 patients (3.48%) developed postoperative DSSIs in the NV group, thereby requiring revision surgeries and parenteral antibiotics treatment versus no DSSIs (0%, 0/100) in the V group. (p = 0.048). The postoperative serum vancomycin levels were undetectable and no vancomycin related side effects was encountered. The mean vancomycin concentration of drainage at postoperative days 1 and 3 were 517.96±174.4 and 220.14±102.3 μg/mL, respectively. At final follow-up, there was no statistical difference observed in terms of clinical and radiologic outcomes.

Conclusions  Our vancomycin protocol may reduce the incidence of DSSI in degenerative lumbar fusion surgery without affecting bony fusion.
Deep Surgical site infection (DSSI) is one of the most serious problems in orthopedic surgery and can be more complicated with implants in the joints or bones. To reduce the incidence of DSSI, delivery of local antibiotics has become popular in orthopedic surgery [1]. The benefit of local antibiotic delivery is obtaining high levels of antibiotics without increasing systemic toxicity [1]. Bone cement is one of the gold materials for local antibiotic delivery in orthopedic surgery [1]. Moreover, another delivery system, such as bone graft, either autograft, allograft or synthetic bone, has been clinically used in treatment of infective non-union of tibia [2, 3].

The infection rates following spinal instrumented fusion have been reported up to 7.7% [4, 5]. In order to reduce DSSI following spinal instrumented fusion surgery, local application of vancomycin powder on superficial or subfascial tissue or both [6–10] has been reported with successful results. However, Eder C [11] reported osteoblast proliferation was significantly inhibited with a vancomycin level above 3 mg/cm² and cell death exceeding 6 mg/cm² in a in vitro study. Besides, significant disability and pain have been reported in patients with pseudarthrosis following spinal instrumented fusion surgery [12]. Therefore, it is important for spine surgeons to find a balance between decreasing DSSI and avoiding non-union in terms of local application of vancomycin.

Moreover, papers regarding the effect of autogenic bone graft (ABG) as a local vancomycin delivery system to prevent DSSI in degenerative lumbar spinal fusion surgery was not much [8, 13]. Accordingly, it is important for spine surgeons to investigate the effects of vancomycin powder mixing with ABG not only on DSSI prevention but bony fusion interference, especially when applying vancomycin powder in the degenerative lumbar fusion surgery. Therefore, we designed an ambispective study to examine the effects of autogenic bone graft along with bone substitute as a local vancomycin delivery system on preventing DSSI in instrumented fusion for degenerative lumbar spinal disorders, functional outcomes and incidence of non-union were also investigated and compared with those who did not use vancomycin powder.

**Methods**

From January through December, 2015, a one-year prospective study was conducted using vancomycin powder (VP) mixed with autogenous bone graft and bone substitute for those patients with degenerative lumbar disorders who needed surgical intervention with posterior decompression, instrumentation and fusion and were grouped as V group after getting the approval of internal review board at our hospital. Then a retrospective study was conducted with the patients not using VP and grouped as NV group from December, 2013 through December, 2014 (Fig. 1). The indications of surgery were persistent back and radicular pain with neurologic claudication and failure of conservative treatment for at least 3 months. All instrumentation including transpedicle screws and transforminal lumbar interbody fusion (TLIF) cage was approved by the National Health Insurance Bureau and done by one senior surgeon (S-T W). The patients who had previous spinal surgery or history of allergic reaction to vancomycin were excluded. Patients’ demographic data, microbiology reports, fusion status and functional outcomes regarding Oswestry disability index (ODI) and visual analogue scale (VAS) for back and leg pain were recorded and analyzed preoperatively and at latest follow-up.

Prophylactic antibiotic was given intravenously with 1 gm cephalosporin 30 min before skin incision and redosing at a 4-h interval intra-operatively. After operation, 1 gm cephalosporin was given at an 8-h interval and gentamicin 80 mg at a 12-h interval for three days. Traditional open posterior decompression, instrumentation and fusion were carried out with autogenous bone graft (ABG) from the bone chips of decompressed laminae and spinous processes and mixed with β-tricalcium phosphate bone substitute (chronOS®, DePuy Synthes, West Chester, PA, USA) at a 1:1 volume ratio. Then, 1 gm vancomycin powder (Gentle Pharmaceutical Co., Yunlin, Taiwan) was mixed homogenously with the mixture of ABG and bone substitute for 2 or 3-level and 2 gm for more than 3-level. In order to prevent vancomycin being washed out by blood, the mixture was left undisturbed for at least 30 min to allow the vancomycin powder being adhered adequately to the mixture of bone graft.

Intraoperative meticulous irrigation with normal saline using a pulsatile lavage system (Interpulse; Stryker Corp, Kalamazoo, MI, USA) was routinely performed for both V and NV groups throughout the whole procedure (Fig. 2). Finally, the wound was closed in the usual way.
manner with a suction drainage tube left in. Patients were allowed ambulating with an orthosis at post-op days 3 or 4 after removal of drainage.

Vancomycin concentrations in the V group were checked at post-operative day 1 (POD1) and 3 (POD3) following surgery for both serum and surgical site, which was collected from the drainage, and were analyzed by Architect iVancomycin (Abbott, Wiesbaden, Germany) using the Architect i1000 SR analyzer (Abbott Laboratories, North Chicago, IL, USA). Architect iVancomycin is

**Fig. 1** The study design of this ambispective study. The study was composed of retrospective study (non-vancomycin, N=86) before the vancomycin protocol and prospective study (vancomycin, N=110) after the protocol set up

**Fig. 2** The vancomycin protocol and our methods of infection were controlled step by step during the whole operation
an in vitro chemiluminescent microparticle immunoas-
say for the quantitative measurement of vancomycin in
human serum or plasma.

After the operation, all patients were followed up at
post-operative 3-month, 6-month, 12-month and annu-
ally. Dynamic flexion and extension lateral radiographs
were performed at post-operative 2-year to evaluate
whether solid fusion was achieved. Radiographic pedicle
screw loosening was defined as a 1 mm or greater radio-
ulucent halo surrounding the pedicle screw (halo sign and
double halo sign), which was adopted from Sanden B
et al. [14].

The posterolateral fusion was evaluated using Lenke
criteria [15] (Table 1). The definition of cage fusion was
bridging bone across the disc space from one vertebrae
to the adjacent level using Brantigan, Steffee, Fraser
(BSF) scale [16]. Two spine surgeons (P–H Chou and Y-C
Yao), who were not involved in the surgery, evaluated the
fusion status, respectively. Follow-up CT scan was not
routinely arranged for fusion evaluation because of cost
reduction, reduction of radiation exposure, artifacts by
the metallic implants and the policy of Taiwan’s National
Health Insurance.

Once DSSI was suspected, magnetic resonance image
(MRI) of lumbar spine and serum C-reactive protein
(CRP) were checked. The definition of DSSI was defined
as "pedicle screw fluid sign" according to Kimura H
et al. [17] and TLIF cage as well. CT-guided biopsy was
arranged and the diagnosis was confirmed by either his-
topathology or bacterial culture. Specimen from CT-
guided biopsy were placed on 10% aerobic and anaerobic
blood agar plates. For identification of Staphylococcus
aureus, matrix-assisted laser desorption-ionization time-
of-flight mass spectrometry (bioMérieux) was used.
Susceptibilities of Staphylococcus aureus isolated to
antimicrobial agents were determined by Vitek2 system
(bioMérieux). The antimicrobial susceptibilities were
interpreted according to the Clinical and Laboratory
Standards Institutes (CLSI) breakpoint [18]. Specimen
from CT-guided biopsy were fixed in 10% neutral buff-
ered formalin and decalcified by immersion in Shandon
TBD-1 rapid decalcifier containing 10% hydrochloric acid
(Thermo Electron Corporation) for 1 h. The decalcified
material was then processed and embedded in paraffin,
sectioned in 3 to 5 μm slices and stained with heamoxy-
lin and eosin. Stained sections were examined with atten-
tion by experienced pathologists using light microscopy
under lower-powered (X40) and high-powered (X400),
respectively.

Once the diagnosis of DSSI being established, effective
intravenous antibiotics were administrated for at least
6 weeks or until the ESR and CRP level returned to nor-
mal, which were checked weekly, and were followed by
oral antibiotics for another 6 weeks.

Statistical analysis was performed using SPSS for win-
dows (version 15.0; SPSS, Chicago, Illinois, 1999). Stu-
dent’s t test was used for numerical data and chi square
test for categorical data. A p value less than 0.05 consid-
ered statistical significance. To determine whether these
tests were appropriately powered, power analysis was
also performed using G*Power software (Heinrich-Heine
Universität Düsseldorf, Düsseldorf, Germany).

Results

From January through December, 2015, 110 patients
were prospectively enrolled as vancomycin (V) group,
and 86 patients without using intra-operative vancomy-
cin (non-vancomycin, NV group) were retrospectively
enrolled from December, 2013 through December, 2014.
The overall average age of the patients was 73.1 year-old
(range, 49 to 82) at operation, 73.7 year-old for the V
group and 72.5 year-old for the NV group. There was no
statistical significance between these two groups regard-
ing pre-operative demographic data and functional out-
comes. The mean follow-up time was 38 months and
53 months for the V and NV groups, respectively, which
was significantly longer for the NV group. (Table 2).

The average vancomycin concentrations obtained from
the drain were 517.96±161.72 μg/mL (range, 107.9–
932.4) and 220.14±102.3 μg/mL (range, 74.3–591.2) at
post-operative day 1 and 3 (POD 1 and POD 3), respec-
tively, whereas vancomycin was undetectable in the
serum (Table 3). There was no adverse event related to
the local application of vancomycin such as red man syn-
drome, allergic reaction, ototoxicity or renal toxicity.

Table 1 Lenke classification for lumbar posterolateral fusion assessments

| Grading | Fusion | Description |
|---------|--------|-------------|
| A       | Solid  | big trabeculated fusion, bilaterally |
| B       | Possibly Solid | big fusion mass at unilateral with a small fusion mass at the contralateral side |
| C       | Probably Not Solid | small, thin fusion masses bilaterally with apparent crack |
| D       | Definitely Not Solid | graft resorption bilaterally or fusion mass with an obvious bilateral pseudarthrosis |

The fusion criteria was adopted from J Spinal Disord 1992;5:433–42
No infection (0/110, 0%) was encountered in the V group, but 3 patients (3/86, 3.48%) had DSSI in the NV group, which was statistically significant being observed in the NV group ($P=0.048$) (Table 4). All 3 patients had severe back pain after surgery and fluid accumulation sign around screws or TLIF cage in the MRI. Methicillin-resistant Staphylococcus aureus (MRSA) was cultured within three months of the index operation in two patients, and the other patient had a negative culture and was diagnosed by histopathology. One patient needed an anterior surgery to remove the loosening cage and fusion with tricortical iliac strut graft. Another one patient only needed removal of pedicle screws, and the other one could be treated with parenteral antibiotic alone without removal of implants.

The mean operative time was 281 and 285 min in the V and NV groups, respectively ($P=0.687$). The mean estimated blood loss was 282 and 297 mL in the V and NV groups, respectively ($P=0.717$) (Table 2). The surgical complications besides DSSI were similar between the two groups ($P=0.350$) (Table 4): 2 patients experienced screws breakage or loosening in both groups, and 2 in the NV group due to DSSI.

Total 232 cages were placed in the 196 patients with mean 1.18 cages insertion (range, 0–3) in each operated patient. According to the BSF scale, the interbody fusion rates were similar between the two groups ($p=0.436$). One patient was excluded in the NV group due to DSSI and underwent implant removal surgery. By the Lenke classification, the posterolateral fusion rates were also similar between the two groups ($P=0.563$) (Table 5). The functional outcomes regarding ODI were similar between these two groups at latest follow-up ($P=0.463$) (Table 4). The visual analogue scale (VAS) for back and leg pain were also similar between two groups ($P=0.581$ and $P=0.121$), respectively.

### Table 2 Pre-operative demographic data between two groups

|                           | Vancomycin (V) | Non-Vancomycin (NV) | $P$ value |
|---------------------------|----------------|---------------------|-----------|
| No. of Patients           | 110            | 86                  |           |
| Mean Age at Op. (years)   | $73.7 \pm 9.8$ (49–82) | $72.5 \pm 10.6$ (55–81) | 0.413     |
| Body Mass Index (BMI)     | $21.8 \pm 3.5$ (15.9–32.9) | $22.2 \pm 3.8$ (16.7–34.6) | 0.445     |
| Gender                    |                |                     | 0.689     |
| Male                      | 48             | 40                  |           |
| Female                    | 62             | 46                  |           |
| Pathologic Lesions        |                |                     | 0.927     |
| 2 levels                  | 36             | 27                  |           |
| 3 levels                  | 58             | 47                  |           |
| 4 levels                  | 16             | 12                  |           |
| Co-morbidities            |                |                     | 0.577     |
| Diabetes mellitus         | 23             | 14                  |           |
| BMI > 30                  | 2              | 3                   |           |
| Rheumatoid arthritis      | 0              | 1                   |           |
| Steroid Used              | 5              | 4                   |           |
| Smoker                    | 26             | 14                  |           |
| Functional Outcomes       |                |                     |           |
| Visual analogue scale over back | $4.2 \pm 2.1$ (2–8) | $4.3 \pm 2.4$ (1–8) | 0.746     |
| Visual analogue scale over leg | $50.0 \pm 1.6$ (4–7) | $49.8 \pm 1.8$ (4–8) | 0.682     |
| Oswestry Disability Index (ODI) | $54.8 \pm 12.6$ (38–70) | $55.7 \pm 13.3$ (24–74) | 0.629     |
| Mean follow-up times (months) | $38.3 \pm 6.2$ (36–48) | $53.1 \pm 5.7$ (48–60) | 0.000     |

All numbers were presented with mean± standard deviation (range), with the range in parentheses.

### Table 3 Vancomycin levels in serum and drain in vancomycin group

| Post-operative day | 1st (POD 1) | 3rd (POD 3) |
|--------------------|-------------|-------------|
| Vancomycin Drain   | 517.96±161.72 (107.9–932.4) | 220.14±102.3 (74.3–591.2) |
| Concentration      | Serum       | Serum       |
|                   | <0.24       | <0.24       |

$N=110$ patients in vancomycin group, the unit of vancomycin concentration wasμg/mL.

The results were presented as mean± SD with the range in parentheses.

We used ELISA method to measure the vancomycin concentration.
Discussion

Postoperative DSSI following spinal fusion surgery is a challenging complication with a potentially catastrophic outcome, as well as significantly increases burden to the patient, patient's family, and the healthcare system. The most common organism isolated from DSSI following spinal fusion surgery is Staphylococcus aureus [19]. However, parenteral vancomycin usage was not as effective as cephalosporin in preventing SSIs in clean orthopedic surgery [20]. Besides, side effects, such as infusion-related toxicities, nephrotoxicity, red man syndrome and ototoxicity, following parenteral vancomycin could be commonly occurred, even within therapeutic concentration [21]. Although vancomycin impregnated cement is one of the convincing methods to prevent deep infection during knee arthroplasty [22], the role of intra-wound vancomycin power (VP) on

Table 4 Surgical results and complications between two groups

|                          | Vancomycin (V) | No Vancomycin (NV) | P value |
|--------------------------|----------------|--------------------|---------|
| Numbers of Patients      | 110            | 86                 |         |
| Blood Loss (mL)          | 282 ± 280 (150–1100) | 297 ± 295 (140–1000) | 0.717   |
| Operative Times (mins)   | 281 ± 72 (200–400)    | 285 ± 63 (220–410)   | 0.687   |
| Deep Surgical Site Infection (DSSI) | 0 (0%)          | 3 (3.48%)          | 0.048*  |
| Surgical-Related Complications (patients) |                 |                    | 0.350   |
| Screws breakage or loosening | 2              | 4                  |         |
| Cage Dislodge or migration | 0              | 1                  |         |
| Incidental Durotomy      | 2              | 2                  |         |
| Vancomycin-Related Complications (patients) |             |                    |         |
| Red Man syndrome         | 0              | NA                 |         |
| Allergic reaction        | 0              | NA                 |         |
| Renal toxicity           | 0              | NA                 |         |
| Ototoxicity or transient hearing loss | 0              | NA                 |         |
| Systemic Absorption (Detectable Serum Vancomycin) | 0              | NA                 |         |
| Functional Outcomes      |                |                    |         |
| Visual analogue scale (VAS) over back | 1.8 ± 1.3 (1–5) | 1.2 ± 1.2 (0–4) | 0.581   |
| Visual analogue scale (VAS) over leg | 1.3 ± 0.4 (1–4) | 1.2 ± 0.5 (0–3) | 0.121   |
| Oswestry Disability Index (ODI) | 31.8 ± 9.6 (16–48) | 32.9 ± 10.1 (24–50) | 0.438   |

The percentage was presented in parentheses, NA meant Non-appreciable, f/u meant follow-up

2 patients had S1 screws loosening in the V group at latest f/u
2 patients had S1 screws loosening in the NV group at latest f/u. (2: S1 screws, 2: infective non-union)

Table 5 Results of bone fusion at latest follow-up between two groups

|                          | Vancomycin (V) | No Vancomycin (NV) | P value |
|--------------------------|----------------|--------------------|---------|
| Numbers of Patients      | 110            | 86                 |         |
| Numbers of Discs with Cages Insertion | 132          | 100                |         |
| Posterolateral Fusion Evaluated by Lenke Classification (of patients) |  |  | 0.563   |
| A (Definite Solid)       | 40             | 31                 |         |
| B (Possibly Solid)       | 29             | 24                 |         |
| C (Probably Not Solid)   | 38             | 27                 |         |
| D (Definitely Not Solid) | 3              | 4                  |         |
| Interbody fusion evaluated by Brantigan, Steffee and Fraser definition (of cages) |  |  | 0.463   |
| BSF-1 (radiographical pseudarthrosis) | 0              | 1                  |         |
| BSF-2 (radiographical locked pseudarthrosis) | 11            | 10                 |         |
| BSF-3 (radiographical fusion) | 121           | 89                 |         |

+ 1 patient underwent cage removal surgery due to infective non-union and loosening during follow-up
DSSI prophylaxis in degenerative lumbar spine fusion surgery is still elusive [6–10, 23].

Bone grafting as a deliver system for VP as adjuvant for DSSI prophylaxis has been reported [8, 13], which was similar to our protocol. Gans I [13] reported 500 mg VP was distributed subfascially and mixed with bone graft in pediatric spine deformity surgery regarding fusion, growing rod, and vertical expandable prosthetic titanium rib (VEPTR). However, the paper focused on the vancomycin-related systemic safety concerns such as anaphylaxis, nephrotoxicity, red man syndrome thrombophlebitis or rash for local application of VP in pediatric patients and did not report the impact of VP on bone fusion. Three (3.4%) in the totally 87 operated pediatric deformity correction still got DSSI at 1 to 2-month postoperatively in the cases series report.

Sweet FA et al. [8] reported a retrospective cohort study of applying 2 gm VP locally in almost all kinds of spine instrumented fusion surgeries including transforaminal lumbar interbody fusion, revision surgery, osteotomy, adolescent idiopathic scoliosis, adult scoliosis, trauma and tumor. They spread 1 gm VP deeply and superficially, and the other 1 gm VP was mixed with the bone grafting materials, which was different to our vancomycin protocol, including diversity of the diseases and sprinkling in the wound. In our current study, we only focused on degenerative lumbar fusion surgery, and employed VP mixed with the bone grafting materials without sprinkling in the wound. Moreover, the definition of pseudarthrosis was not clearly described in the Sweet’s study [8], which was a major concern for spine surgeons when using VP locally. In our study, we adopted the fusion criteria using Lenke criteria [15] and BSF scale [16] for posterolateral and anterior interbody fusions respectively, which were widely accepted in the literature besides CT scan.

The overall incidences of DSSI in selective degenerative lumbar fusion surgery, adult spine deformity correction, spine trauma surgery and revision instrumented lumbar fusion ranged from 2.8% to 6% [24], 3.5% to 4.5% [25, 26], 3% to 9.4% [27, 28] and 2.2% to 4.5% [29, 30], respectively. The incidence of DSSI in selective degenerative lumbar fusion surgery is not an uncommon complication, which may have devastating consequence, and spine surgeons need to make an early diagnosis if any clinically suspicious.

Ghobrial GM [31] reported intra-wound vancomycin provided selective pressure with increased gram negative and polymicrobial infection. Chotai S reported [32] the occurrence of DSS caused by S aureus was lower in the V group as compared to those in the NV group (32% vs 65%). A gram-negative pathogen was detected in 28% and 12.5% of patients with DSSI in the V and NV groups, respectively. The incidence of polymicrobial (mixed with anaerobic and aerobic) was similar between two groups (5% for NV group, 4% for V group). Accordingly, significant difference of cultured organisms was observed in the vancomycin group [31, 32]. Neither these papers [31, 32] nor our series were investigated any vancomycin-resistant organisms in DSSI. Clinicians have to be aware of vancomycin-related selective pressure and immune-burden to avoid resistant organism and find a dynamic balance between DSSI prevention and local antibiotics application.

Minimal inhibitory concentration (MIC) is defined as the lowest concentration of antimicrobial that will inhibit the visible growth of microorganism following overnight incubation [33]. The mean MIC of vancomycin for MRSA has been reported 1.5–2 μg/mL [34]. In our study, the average vancomycin levels from the surgical site were 517.96 ± 161.72 and 220.14 ± 102.3 μg/mL at POD 1 and POD 3 respectively, which was much higher than the MIC of MRSA and might explain the effect of vancomycin on preventing DSSI postoperatively. Moreover, an undetectable serum vancomycin concentration may explain the little effects on systemic toxicity.

Regarding the inhibition of pre-osteoblast and osteoblast proliferation, three in vitro studies have been reported the vancomycin concentration greater than the 3 mg/cm², 2000 and 5000 μg/mL could inhibit proliferation of pre-osteoblast and osteoblast [11, 35, 36], which might lead to nonunion in vivo. The local vancomycin concentrations at POD 1 were 462 and 251 μg/mL have been reported by Sweet FA [8] and Armaghani [37], respectively, and 128 μg/mL at POD 3 by Sweet FA [8]. In our study, the average vancomycin levels were 517.96 ± 161.72 μg/mL (range, 107.9–932.4) and 220.14 ± 102.3 μg/mL (range, 74.3–591.23) at POD 1 and POD 3, respectively, which did not reach the inhibitory concentration for osteoblast. Therefore, the mixture of ABG and bone substitute could serve as a local vancomycin delivery system to maintain high vancomycin concentrations without jeopardizing bony fusion.

There are several drawbacks in our study including patients’ number is not enough to reach and adequate power and draw a solid conclusion. CT scan was not use for fusion evaluation, which is more reliable on examining fusion. Selection bias due to ambispective study was also a weakness. Moreover, intra- and inter-observer reliability for fusion assessment was not checked. There have been many articles on the topical of local vancomycin to reduce the risk of infection after orthopaedic surgery [3, 38, 39]. Moreover, vancomycin impregnated bone graft has been also widely used in spinal surgery [40–42]. Therefore, a prospective randomized study with an adequate patient number is needed to clarify the benefits of vancomycin impregnated autogenous bone graft and
bone substitute on preventing DSSI following degenerative lumbar spine fusion surgery.

Conclusions
Our study merely showed ABG with bone substitutes might be a local vancomycin delivery system to maintain high local concentration of vancomycin and to decrease DSSI incidences without detectable serum concentration and systemic adverse event, interfering posterolateral and interbody fusion or poor functional outcomes. Sterilized preparation, prophylactic antibiotics, environment and aseptic concepts for the staffs in the operating room are old fashion and still play important roles in preventing DSSI [43] and have to be emphasized besides application of local vancomycin.

Abbreviations
DSSI  Deep surgical site infection  
ABG  Autogenous bone graft  
V  Vancomycin  
NV  Non-vancomycin  
VP  Vancomycin powder  
TLIF  Transforaminal lumbar interbody fusion

Acknowledgements
We thank Hsin-Yi Huang from the Biostatistics Task Force, Taipei Veterans General Hospital, for the statistical assistance.

Authors’ contributions
PHC: drafting manuscript, acquisition of data, analysis and interpretation, HHL: acquisition of data, analysis and interpretation, YCY: analysis and interpretation, PHC: drafting manuscript, acquisition of data, analysis and interpretation, HHL: statistical assistance.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Availability of data and materials
All data generated or analysed during this study are included in this published article.

Declarations
Ethics approval and consent to participate
The institutional review board of our hospital (Taipei Veterans General Hospital) approved the research protocol (2017-10-008A). The requirement for informed consent was waived because of the retrospective nature of this study for participants who did not use vancomycin powder. Informed consent was signed by participants for using vancomycin powder intraoperatively. The requirement for informed consent was waived because of the retrospective nature of this study for participants who did not use vancomycin powder. This study was performed in accordance with the ethical principles set out in the 1964 Declaration of Helsinki.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Hanssen AD. Local antibiotic delivery vehicles in the treatment of musculoskeletal infection. Clin Orthop Relat Res. 2005;437:91–6.
2. Chan YS, Ueng SW, Wang CJ, Lee SS, Chen CY, Shin CH. Antibiotic-impregnated autogenous cancellous bone grafting is an effective and safe method for the management of small infected bimal defects: a comparison study. J Trauma. 2000;48(2):246–55.
3. Chen CE, Ko YJ, Pan CC. Results of vancomycin-impregnated cancellous bone grafting for infected bimal nonunion. Arch Orthop Trauma Surg. 2005;125(6):369–75.
4. Kanayama M, Hashimoto T, Shigenobu K, Oha T, Togawa D. Effective prevention of surgical site infection using a Centers for Disease Control and Prevention guideline-based antimicrobial prophylaxis in lumbar spine surgery. J Neurosurg Spine. 2007;6(4):327–9.
5. Olsson MA, Nepple JJ, Riew KD, Lenke LG, Bridwell KH, Mayfield J, Fraser VJ. Risk factors for surgical site infection following orthopaedic spinal operations. J Bone Joint Surg Am. 2008;90(1):62–9.
6. Strom RG, Pacione D, Kalhorn SP, Frempong-Boadu AK. Decreased risk of wound infection after posterior cervical fusion with routine local application of vancomycin powder. Spine. 2013;38(12):991–4.
7. Caroome C, Tullar JM, Benton EG Jr, Jones JR, Chaput CD. Intrawound vancomycin powder reduces surgical site infections in posterior cervical fusion. Spine. 2013;38(14):1183–7.
8. Sweet FA, Roh M, Sliva C. Intrawound application of vancomycin for prophylaxis in instrumented thoracic/ lumbar fusions: efficacy, drug levels, and patient outcomes. Spine. 2011;36(24):2084–8.
9. O’Neill KR, Smith Jr, Abtahi AM, Archer KR, Spengler DM, McGirt MJ, Devin CJ. Reduced surgical site infections in patients undergoing posterior spinal stabilization of traumatic injuries using vancomycin powder. Spine J. 2011;11(7):641–6.
10. Tubaki VR, Rajasekaran S, Shetty AP. Effects of using intravenous antibiotic only versus local intrawound vancomycin antibiotic powder application in addition to intravenous antibiotics on postoperative infection in spine surgery in 907 patients. Spine. 2013;38(25):2149–55.
11. Eder C, Schenk S, Trifinopoulos J, Kulekci B, Kienz M, Schildbock S, Ogon M. Does intrawound application of vancomycin influence bone healing in spinal surgery? European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society 2015.
12. Dede O, Thullier D, Pekmezci M, Ames CP, Hu SS, Berven SH, Deviren V. Revision surgery for lumbar pseudarthrosis. Spine J. 2015;15(5):977–82.
13. Gans I, Dormans JP, Spiegel DA, Flynn JM, Sankar WN, Campbell RM, Baldwin KD. Adjunctive vancomycin powder in pediatric spine surgery is safe. Spine. 2013;38(19):1703–7.
14. Sanden B, Oderud C, Petten-Mallmin M, Johansson C, Larsson S. The significance of radiolucent zones surrounding pedicle screws. Definition of screw loosening in spinal instrumentation. J Bone Joint Surg Br. 2004;86(3):457–61.
15. Lenke LG, Bridwell KH, Bullis D, Betz RR, Baldus C, Schoenecker PL. Results of in situ fusion for ischmic spondylolisthesis. J Spinal Discorid 1993;5(6):433–42.
16. Fogel GR, Toohey JS, Neidre A, Brantigan JW. Fusion assessment of posterior lumbar interbody fusion using radiolucent cages: X-ray films and helical computed tomography scans compared with surgical fusion. Spine J. 2008;8(4):570–7.
17. Kimura H, Shikata J, Odate S, Soeda T. Pedicle Screw Fluid Sign: An Indication on Magnetic Resonance Imaging of a Deep Infection After Posterior Spinal Instrumentation. Clin Spine Surg. 2017;30(4):169–75.
36. Rathbone CR, Cross JD, Brown KV, Murray CK, Wenke JC. Effect of various
35. Antoci V Jr, Adams CS, Hickok NJ, Shapiro IM, Parvizi J. Antibiotics for local
34. Lepe JA, Dominguez-Herrera J, Pachon J, Aznar J. Determining accurate
33. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, Alamo D,
32. Ghobrial GM, Thakkar V, Andrews E, Lang M, Chitale A, Oppenlander ME,
31. Smith JS, Shaffrey CI, Sansur CA, Berven SH, Fu KM, Broadstone PA,
29. Machino M, Yukawa Y, Ito K, Nakashima H, Kato F. Posterior/anterior com‑
27. Machino M, Yukawa Y, Ito K, Nakashima H, Kato F. Posterior/anterior com‑
26. Haddad S, Núñez-Pereira S, Pigrau C, Rodríguez-Pardo D, Vila-Casademat‑
25. Pull ter Gunne AF, van Laarhoven CJ, Cohen DB: Incidence of surgical site
23. Martin JR, Adogwa O, Brown CR, Bagley CA, Richardson WJ, Lad SP,
22. Chiu FY, Lin CF. Antibiotic-impregnated cement in revision total knee
21. Moellering RC Jr. Vancomycin: a 50-year reassessment. Clin Infect Dis.
20. Kanj WW, Flynn JM, Spiegel DA, Dormans JP, Baldwin KD. Vancomycin
18. Wang JT, Hsu LY, Lauderdale TL, Fan WC, Wang FD. Comparison of
17. Horii C, Yamazaki T, Oka H, Azuma S, Oghara S, Okazaki R, Kawamura N,
16. Kanji JW, Flynn JM, Spiegel DA, Dormans JP, Baldwin KD. Vancomycin
15. Antoci V Jr, Adams CS, Hickok NJ, Shapiro IM, Parvizi J. Antibiotics for local
14. Lepe JA, Dominguez-Herrera J, Pachon J, Aznar J. Determining accurate
13. Soler M, Mora JS, de la Serna A, Badia X, Campos E, Cases J, et al. Antimicrobial
12. Sasso RC, Garrido BJ. Postoperative spinal wound infections. J Am Acad
11. Pull ter Gunne AF, van Laarhoven CJ, Cohen DB. Incidence of surgical site
10. Martin JR, Adogwa O, Brown CR, Bagley CA, Richardson WJ, Lad SP,
9. Martin JR, Adogwa O, Brown CR, Bagley CA, Richardson WJ, Lad SP,
8. Martin JR, Adogwa O, Brown CR, Bagley CA, Richardson WJ, Lad SP,
7. Martin JR, Adogwa O, Brown CR, Bagley CA, Richardson WJ, Lad SP,
6. Martin JR, Adogwa O, Brown CR, Bagley CA, Richardson WJ, Lad SP,
5. Martin JR, Adogwa O, Brown CR, Bagley CA, Richardson WJ, Lad SP,
4. Martin JR, Adogwa O, Brown CR, Bagley CA, Richardson WJ, Lad SP,
3. Martin JR, Adogwa O, Brown CR, Bagley CA, Richardson WJ, Lad SP,
2. Martin JR, Adogwa O, Brown CR, Bagley CA, Richardson WJ, Lad SP,
1. Martin JR, Adogwa O, Brown CR, Bagley CA, Richardson WJ, Lad SP,